U.K. Offers $13.4 Million To India For Cheap AIDS, Malaria Drugs
This article was originally published in PharmAsia News
Executive SummaryThe United Kingdom is offering more than $13.4 million to fund Indian drug makers that make lower-cost drug to fight AIDS and malaria. The program is set to begin next year and last through 2012 to provide technical support to firms that carry drugs through the registration stage and are willing to negotiate prices for them. The program is estimated to have a potential to help more than 11 million people gain access to treatment during the period. The U.K. government is working with the Clinton Foundation to help Indian drug makers make cheaper drugs for the diseases. (Click here for more
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.